Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(15):1023; doi:10.1093/jnci/djj346
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Whitworth, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Whitworth, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

MEMO TO THE MEDIA

Press Release

Addition of Topotecan to Standard Treatment is Not Recommended for Ovarian Cancer Patients

Ariel Whitworth

jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute

The first 10% of the full text of this article appears below.

The drug topotecan does not increase survival for ovarian cancer patients when used with standard chemotherapy in first-line treatment and is not recommended for future use, according to a phase III study in the August 2 issue of the Journal of the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?